Insmed | INSM - Pre Tax Profit


Insmed reported $-326.93M in Pre-Tax Profit for its fiscal quarter ending in December of 2025.





Pre Tax Profit Change Date
BioMarin Pharmaceutical USD -26.32M 324.19M Sep/2025
Cytokinetics USD -183.03M 123.15M Dec/2025
DBV Technologies USD -33.16M 8.6M Sep/2025
Gilead Sciences USD 3.64B 1.21B Sep/2025
Heron Therapeutics USD -2.95M 14.54M Dec/2025
Insmed USD -326.93M 41.77M Dec/2025
Novartis USD 5.17B 637M Sep/2025
Regeneron Pharmaceuticals USD 1.76B 244.6M Sep/2025
Sarepta Therapeutics USD -407.67M 213.63M Dec/2025
Ultragenyx Pharmaceutical USD -128M 51.54M Dec/2025
Vertex Pharmaceuticals USD 1.3B 15.8M Sep/2025